When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals

The volume of shares traded in a session often gets a passing mention in the financial press until a stock experiences unusually high volume. That's because volume can provide an important measure of the conviction behind a stock's price movement.

Stocks that trade at a multiple above their average daily trading volume are considered to be experiencing unusual volume. Any stock, from blue-chip large-cap stocks to speculative penny stocks, can experience high volume.

It typically won't take long for stocks to revert to their average volume. But even when they do, the catalyst for the volume spike may still be present. That's the case for three small-cap stocks that have recently shown unusually high trading volume for completely different, but valid reasons.

Is High Volume a Signal or Noise?

A volume spike is just a signal that something changed. Before acting on stocks with unusual volume, it's important to understand why volume is spiking. It's usually based on news of some sort. But sometimes that news is more relevant to a related stock in the company's sector, or it may simply be noise.

For example, insider selling gets a lot of attention, but it often has nothing to do with a stock's fundamentals. Likewise, concerns about the relationship between artificial intelligence (AI) and software drove up volumes across many stocks, even those reporting strong earnings.

Conversely, a new product launch may drive up trading volume on expectations of stronger sales volume and higher earnings. Volume can also climb due to high short interest. When many investors with short positions have to cover their positions, a short squeeze can occur.

Each example shows why unusually high trading volume by itself is not a reason to buy or sell a stock. They also illustrate why three small-cap stocks may be worth a look.

Canada Goose: The Beaten-Down Stock With a Contrarian Setup

Unusually high volume can be positive or negative for a stock. In the case of Canada Goose NYSE: GOOS, the brief periods of high volume in the last year have mostly brought the price lower. As of this writing, GOOS trades near its 52-week low of $8.10.

The reason is found in the company's name. This is a Canadian company that will be directly affected by the escalating trade dispute between the United States and Canada.

According to data from Bank of America, a 50% tariff on Canadian goods (which kicked in on Aug. 22) raises the company's effective tariff rate on U.S. imports to 41.4% from 4.3%. That hits Canada Goose on the bottom line, with year-over-year (YOY) numbers already lower due to soft traffic.

However, revenue is still growing YOY, and the company's luxury products come with an attractive gross margin of over 60%. That's particularly important because the company caters to a consumer who is less impacted by sticky inflation and affordability concerns.

For investors with room in their portfolio for a beaten-down contrarian stock with solid fundamentals that could offer asymmetric upside in a category rebound, GOOS is one to consider.

Capital Clean Energy Carriers: An Under-the-Radar Steady Compounder

Capital Clean Energy Carriers NASDAQ: CCEC is on the other end of the volume story. The company has seen spikes in trading volume because of an ongoing bull case for a normally predictable shipping company.

Geopolitics is the story here. Capital Clean Energy operates a fleet of LNG and gas carriers that is seeing an increase in contracted volume due to rising LNG demand and customers' need to access the company's shipping routes, which run from the United States Gulf Coast to Asia, effectively bypassing the Strait of Hormuz.

In its Q2 2026 earnings report, the company reported a backlog of around $2.9 billion in contracted revenue (up to $4.3 billion with options). That went along with adjusted earnings per share (EPS) that beat estimates by 50%. It explains why CCEC is trading within 10% of its 52-week high and why LNG shipping demand is likely to continue to move the stock higher.

SOPHiA GENETICS: A Biotech That's Getting Re-Rated

SOPHiA GENETICS NASDAQ: SOPH rounds out this group of small-cap stocks. The company operates a cloud-based SaaS platform analyzing genomics, radiomics, and clinical data to guide cancer and rare disease diagnostics.

The company's volume spike is directly tied to its Q2 2026 earnings report, which beat revenue expectations and sent shares up in premarket trading. This is evidence of a genuine re-rating that's underway.

The re-rating case rests on U.S. momentum: American revenue grew 64% year-over-year, and liquid biopsy revenue jumped 80% as the MSK-ACCESS and MSK-IMPACT applications ramped with new hospital customers, including a first pediatric partnership with Children's Hospital of Philadelphia.

The bigger debate is durability. Management calls its network of more than 1,000 institutions across 75 countries a moat "that cannot be bought or replicated," built on a dataset of millions of genomic profiles that improves with every case analyzed.

That's a real advantage internationally, where SOPHiA faces less direct competition. But well-funded rivals and cloud-native AI entrants are circling, and the company is still burning cash, with breakeven adjusted EBITDA not expected until late 2026. For investors, the volume spike reflects genuine acceleration, but the long-term bull case remains unsettled.

Should You Invest $1,000 in Canada Goose Right Now?

Before you consider Canada Goose, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canada Goose wasn't on the list.

While Canada Goose currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here